Stryker Corporation $SYK Stock Bought by International Assets Investment Management LLC

Key Points

• International Assets Investment Management increased its Stryker stake by 1,432.8% in the third quarter, bringing its holdings to 25,000 shares valued at approximately $6.9 million. Institutional investors collectively own 77.09% of the company.
• Stryker’s third-quarter revenue rose 7.6% year over year to $6.52 billion, but both revenue and adjusted EPS of $3.52 fell short of analyst estimates. The company also reduced its 2026 organic sales-growth and adjusted-EPS forecasts amid weaker joint-replacement demand and operational disruptions.
• Analyst sentiment remains a Moderate Buy, though several firms lowered price targets or downgraded the stock to hold; the consensus target is $355.84 versus a reported share price of $291.56. Stryker also pays a quarterly dividend of $0.88, representing a 1.2% annualized yield.

International Assets Investment Management LLC raised its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1,432.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the medical technology company's stock after buying an additional 23,369 shares during the quarter. International Assets Investment Management LLC's holdings in Stryker were worth $6,885,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of SYK. Kampmann Melissa S. lifted its position in shares of Stryker by 0.9% in the third quarter. Kampmann Melissa S. now owns 12,374 shares of the medical technology company's stock worth $3,408,000 after buying an additional 116 shares in the last quarter. Canopy Partners LLC increased its stake in Stryker by 30.7% in the 3rd quarter. Canopy Partners LLC now owns 2,792 shares of the medical technology company's stock worth $769,000 after acquiring an additional 656 shares during the last quarter. Glenview Trust Co increased its stake in Stryker by 839.5% in the 3rd quarter. Glenview Trust Co now owns 42,125 shares of the medical technology company's stock worth $11,601,000 after acquiring an additional 37,641 shares during the last quarter. Harbour Trust & Investment Management Co raised its holdings in shares of Stryker by 1.8% during the 3rd quarter. Harbour Trust & Investment Management Co now owns 49,012 shares of the medical technology company's stock worth $13,497,000 after acquiring an additional 853 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Stryker by 17.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the medical technology company's stock worth $1,494,000 after acquiring an additional 800 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Stock Down 0.1%

Shares of SYK opened at $291.56 on Monday. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60. The business has a fifty day moving average of $292.83 and a 200 day moving average of $324.51. The company has a market cap of $111.83 billion, a PE ratio of 31.05, a P/E/G ratio of 1.89 and a beta of 0.78. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $389.33.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to analysts' expectations of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company's revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the company posted $3.19 EPS. On average, sell-side analysts expect that Stryker Corporation will post 14.85 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, September 30th. Stryker's dividend payout ratio is 37.49%.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Insiders Place Their Bets

In other news, insider Dylan Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 over the last 90 days. Insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their target price on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a report on Friday, July 31st. BMO Capital Markets reissued an "outperform" rating and issued a $309.00 price objective on shares of Stryker in a research note on Friday. Sanford C. Bernstein restated a "market perform" rating on shares of Stryker in a report on Wednesday, October 7th. Canaccord Genuity Group cut shares of Stryker from a "buy" rating to a "hold" rating and decreased their target price for the company from $385.00 to $300.00 in a research report on Friday. Finally, Royal Bank Of Canada lowered their price target on shares of Stryker from $420.00 to $375.00 and set an "outperform" rating for the company in a report on Friday. Sixteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $355.84.

Stryker Profile

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.